ldb convergenze parallele_mantovani_02
TRANSCRIPT
![Page 1: Ldb Convergenze Parallele_Mantovani_02](https://reader033.vdocuments.site/reader033/viewer/2022052602/559d651b1a28abc6158b4676/html5/thumbnails/1.jpg)
Diego Mantovani, PhD, FBSE
Lab. Biomaterials and Bioengineering
Dept of Min-Met-Materials Eng. Research Center, CHU de Québec
Université Laval
![Page 2: Ldb Convergenze Parallele_Mantovani_02](https://reader033.vdocuments.site/reader033/viewer/2022052602/559d651b1a28abc6158b4676/html5/thumbnails/2.jpg)
www.lbb.ulaval.ca 2
Outline
Introduction The science behind the project – case study PI: what to do? Absolutely patenting (fiction) Absolutely licensing (fiction) The real case Side knowledge …
![Page 3: Ldb Convergenze Parallele_Mantovani_02](https://reader033.vdocuments.site/reader033/viewer/2022052602/559d651b1a28abc6158b4676/html5/thumbnails/3.jpg)
The science behind the project
Grafting biomolecules to vascular prostheses by functionnalisation
Pascale Chevallier, Martin Castonguay, Jean-Francois Pageau, Diego Mantovani , Gaétan Laroche
![Page 4: Ldb Convergenze Parallele_Mantovani_02](https://reader033.vdocuments.site/reader033/viewer/2022052602/559d651b1a28abc6158b4676/html5/thumbnails/4.jpg)
Vascular Prostheses
![Page 5: Ldb Convergenze Parallele_Mantovani_02](https://reader033.vdocuments.site/reader033/viewer/2022052602/559d651b1a28abc6158b4676/html5/thumbnails/5.jpg)
Research Strategies Interfacial Problem
Blood Flow
Expected Obtained
![Page 6: Ldb Convergenze Parallele_Mantovani_02](https://reader033.vdocuments.site/reader033/viewer/2022052602/559d651b1a28abc6158b4676/html5/thumbnails/6.jpg)
Plasma RF
![Page 7: Ldb Convergenze Parallele_Mantovani_02](https://reader033.vdocuments.site/reader033/viewer/2022052602/559d651b1a28abc6158b4676/html5/thumbnails/7.jpg)
Rationale
Modification Surface Functionnalisation
Chemical Functionalities Bio-conjugation
AIM : anchoring specifically bioactive
molecules
Under vacuum
RFGD NH3
NH2
![Page 8: Ldb Convergenze Parallele_Mantovani_02](https://reader033.vdocuments.site/reader033/viewer/2022052602/559d651b1a28abc6158b4676/html5/thumbnails/8.jpg)
RESULTS
1000 800 600 400 200 0 Binding energy (eV)
Virgin commercial prosthesis
Ammonia plasma
x 4
x 4
x 4
C 1s (32.8%)
F 1s (67.2%) F KLL F 2s
C 1s (55.4%) N 1s (12.2%)
F 1s (28.7%)
O 1s (3.7%) F 2s
F KLL
Ammonia plasma + bioactive molecules
F KLL
F 1s (12.7%) O 1s (16.2%) C 1s (57.7%)
N 1s (6.7%) F 2s
Cl 2p (2.11%)
![Page 9: Ldb Convergenze Parallele_Mantovani_02](https://reader033.vdocuments.site/reader033/viewer/2022052602/559d651b1a28abc6158b4676/html5/thumbnails/9.jpg)
Results
Commercial prosthesis Treated prosthesis
![Page 10: Ldb Convergenze Parallele_Mantovani_02](https://reader033.vdocuments.site/reader033/viewer/2022052602/559d651b1a28abc6158b4676/html5/thumbnails/10.jpg)
Platelets
* 5000 * 5000
Gore Tex Treated
![Page 11: Ldb Convergenze Parallele_Mantovani_02](https://reader033.vdocuments.site/reader033/viewer/2022052602/559d651b1a28abc6158b4676/html5/thumbnails/11.jpg)
Cells
[cells] = 5*103 cells/ml during 7 days
Gore Tex Treated
* 20
* 20
![Page 12: Ldb Convergenze Parallele_Mantovani_02](https://reader033.vdocuments.site/reader033/viewer/2022052602/559d651b1a28abc6158b4676/html5/thumbnails/12.jpg)
In vivo - dogs
/ *2000
Gore Tex Treated
![Page 13: Ldb Convergenze Parallele_Mantovani_02](https://reader033.vdocuments.site/reader033/viewer/2022052602/559d651b1a28abc6158b4676/html5/thumbnails/13.jpg)
In vivo (6 mo. dogs)
![Page 14: Ldb Convergenze Parallele_Mantovani_02](https://reader033.vdocuments.site/reader033/viewer/2022052602/559d651b1a28abc6158b4676/html5/thumbnails/14.jpg)
www.lbb.ulaval.ca 14
PI – what to do?
Patent? License? In site development under ultra conservative confidentiality?
![Page 15: Ldb Convergenze Parallele_Mantovani_02](https://reader033.vdocuments.site/reader033/viewer/2022052602/559d651b1a28abc6158b4676/html5/thumbnails/15.jpg)
www.lbb.ulaval.ca 15
Absolutely patenting or absolutely licensing
Why? What? Where? How? Whom? For how long? What?
![Page 16: Ldb Convergenze Parallele_Mantovani_02](https://reader033.vdocuments.site/reader033/viewer/2022052602/559d651b1a28abc6158b4676/html5/thumbnails/16.jpg)
www.lbb.ulaval.ca 16
(partial) Analyses and (some) criteria
Funding: governmental vs risk capital The environment, in term of:
• Risk analysis • Investors
Personal motivation
• Future and prospective consideration • Personal stimuli
![Page 17: Ldb Convergenze Parallele_Mantovani_02](https://reader033.vdocuments.site/reader033/viewer/2022052602/559d651b1a28abc6158b4676/html5/thumbnails/17.jpg)
The real case …
2 patents on the technology 1 patent on a side technology (anti-fog!?) Spin-off (Materium) was created Licenses are under negotiation
University is happy, especially the TTO Scientists also but ... tired
D. Mantovani, 17 www.lbb.gmn.ulaval.ca